Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Development and Evaluation of a Comprehensive Prediction Model for Incident Coronary Heart Disease Using Genetic, Social, and Lifestyle–Psychological Factors: A Prospective Analysis of the UK Biobank
Naderian, Mohammadreza , Norland, Kristján , Schaid, Daniel J. , Kullo, Iftikhar, Naderian, Mohammadreza

Annals of Internal Medicine | December 9, 2024 | Volume: 178 | Issue: 1 | Pages: 1-10

10.7326/annals-24-00716 | PMID 39652873 Get It

Multi Layered Omics Approaches Reveal Glia Specific Alterations in Alzheimer's Disease: A Systematic Review and Future Prospects
İş, Özkan , Min, Yuhao , Oatman, Stephanie R., Daniel, Ann Abraham , Ertekin‐Taner, Nilüfer , Abraham Daniel, Ann , Ertekin-Taner, Nilüfer , Wang, Xue

Glia | December 9, 2024 | Volume: 73 | Issue: 3 | Pages: 539-573

10.1002/glia.24652 | PMID 39652363 Get It

ABSTRACTAlzheimer's disease (AD) is the most common neurodegenerative dementia with multi‐layered complexity in its molecular etiology. Multiple omics‐based approaches, such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and lipidomics are enabling researchers to dissect this molecular complexity, and to uncover a plethora of alterations yielding insights into the pathophysiology of this disease. These approaches reveal multi‐omics alterations essentially in all cell types of the brain, including glia. In this systematic review, we screen the literature for human studies implementing any omics approach within the last 10 years, to discover AD‐associated molecular perturbations in brain glial cells. The findings from over 200 AD‐related studies are reviewed under four different glial cell categories: microglia, oligodendrocytes, astrocytes and brain vascular cells. Under each category, we summarize the shared and unique molecular alterations identified in glial cells through complementary omics approaches. We discuss the implications of these findings for the development, progression and ultimately treatment of this complex disease as well as directions for future omics studies in glia cells.
Right Brain: Cognitive Dissonance
Watson, Sean

Neurology | December 9, 2024 | Volume: 104 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000210154 | PMID 39652809 Get It

Pediatric Advances in Gene Therapies for Hemoglobinopathies
Thompson, Christineil , Gupta, Ashish O. , Ferdjallah, Asmaa

JAMA Pediatrics | December 9, 2024 | Volume: 179 | Issue: 2 | Pages: 117

10.1001/jamapediatrics.2024.5366 | PMID 39652341 Get It

This Viewpoint summarizes recent progress in gene therapy for hemoglobinopathies.
Asthma Among Children With Primary Ciliary Dyskinesia
Zein, Joe , Kim, Hyun Jo , Marozkina, Nadzeya , Gaston, Benjamin , Owora, Arthur Hamie , Marozkina, Nadzeya

JAMA Network Open | December 9, 2024 | Volume: 7 | Issue: 12 | Pages: e2449795

10.1001/jamanetworkopen.2024.49795 | PMID 39652350 Get It

This case-control study uses electronic health record data to assess the association between primary ciliary dyskinesia and asthma in children.
Prolonged time from cross-clamp until normothermic machine perfusion start is associated with an increased risk of early allograft dysfunction following DCD liver transplant
Lee, Charles , Mathur, Amit K. , Mao, Shennen A. , Heimbach, Julie K. , Taner, C. Burcin , Aqel, Bashar , Croome, Kristopher P. , Mao, Shennen A , Croome, Kris P , Taner, Burcin , Heimbach, Julie K , Lee, Charles, Aqel, Bashar A.

Liver Transplantation | December 9, 2024 | Volume: 31 | Issue: 5 | Pages: 616-622

10.1097/lvt.0000000000000548 | PMID 39652008 Get It

There is a paucity of data on the impact of cold ischemia time before the initiation of normothermic machine perfusion (NMP), particularly in more susceptible organs such as livers from donation after circulatory death (DCD) donors. The present analysis aimed to investigate the impact of prolonged time from cross-clamp until NMP start on early allograft dysfunction and other peri–liver transplant (LT) outcomes. All DCD LT performed and placed on NMP at Mayo Clinic Arizona, Florida, and Rochester from January 2022 to March 2024 were included. The decision was made a priori to divide the population into 2 groups based on terciles: typical cross-clamp to on-pump time (lower 2 terciles) versus prolonged cross-clamp to on-pump time (upper tercile; >2 h 45.6 min). Three hundred eighty-four DCD LT undergoing NMP met the inclusion criteria. The rate of early allograft dysfunction was significantly higher in the prolonged cross-clamp to on-pump group (51.2%) compared to the typical cross-clamp to on-pump group (37.6%) (p = 0.01). The prolonged cross-clamp to on-pump group also had higher rates of acute kidney injury and the number of packed red blood cells transfused during LT. No significant difference in ischemic cholangiopathy (2.4% vs. 3.1%; p = 0.68) or graft survival at 12 months was seen between the prolonged cross-clamp to on-pump and typical cross-clamp to on-pump group, respectively. Following cross-clamp, DCD liver grafts should be placed on the NMP pump as quickly as is safely and logistically possible. In cases where delays are unavoidable, such as waiting for biopsy results or liver reallocation with another center, acceptable results can still be achieved, and therefore, livers with prolonged times should still be used.
Concordance and Test-Retest Consistency of Sleep Biomarker-Based Neurodegenerative Disorder Profiling
Levendowski, Daniel J. , Walsh, Christine M., Lee‐Iannotti, Joyce , Salat, David H. , Fischer, Corrine, Mazeika, Gandis, Tsuang, Debby W. , Chahine, Lana M. , Walsh, Christine M. , Berka, Chris , Boeve, Bradley F. , Ferini-Strambi, Luigi , Lewis, Simon J.G. , Neylan, Thomas C. , Louis, Erik K. St.

No container title available | December 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5111150/v1 Get It

Abstract Biomarkers that aid in early detection of neurodegeneration are needed to enable early symptomatic treatment and enable identification of people who may benefit from neuroprotective interventions. Increasing evidence suggests that sleep biomarkers may be useful, given the bi-directional relationship between sleep and neurodegeneration and the prominence of sleep disturbances and altered sleep architectural characteristics in several neurodegenerative disorders. This study aimed to demonstrate that sleep can accurately characterize specific neurodegenerative disorders (NDD). A four-class machine-learning algorithm was trained using age and nine sleep biomarkers from patients with clinically-diagnosed manifest and prodromal NDDs, including Alzheimer’s disease dementia (AD = 27), Lewy body dementia (LBD = 18), and isolated REM sleep behavior disorder (iRBD = 15), as well as a control group (CG = 58). The algorithm was validated in a total of 381 recordings, which included the training data set plus an additional AD = 10, iRBD = 18, Parkinson disease without dementia (PD = 29), mild cognitive impairment (MCI = 78) and CG = 128. Test-retest consistency was then assessed in LBD = 10, AD = 9, and CG = 46. The agreement between the NDD profiles and their respective clinical diagnoses exceeded 75% for the AD, LBD, and CG, and improved when NDD participants classified Likely Normal with NDD indications consistent with their clinical diagnosis were considered. Profiles for iRBD, PD and MCI participants were consistent with the heterogeneity of disease severities, with the majority of overt disagreements explained by normal sleep characterization in 27% of iRBD, 21% of PD, and 26% of MCI participants. For test-retest assignments, the same or similar NDD profiles were obtained for 88% of LBD, 86% in AD, and 98% of CG participants. The potential utility for NDD subtyping based on sleep biomarkers demonstrates promise and requires further prospective development and validation in larger NDD cohorts.
Patient-Centered Care for Ambulatory Surgery
Pai, Sher‐Lu , Ladlie, Beth L., Locke, Keya, Getting, Rosemarie E. Garcia , Ladlie, Beth, Pai, Sher-Lu , Locke, Keya A.

International Anesthesiology Clinics | December 9, 2024 | Volume: 63 | Issue: 1 | Pages: 14-22

10.1097/aia.0000000000000461 | PMID 39651664 Get It

Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
Cathcart-Rake, Elizabeth , Chan, Alexandre , Menendez, Alvaro G. , Markstrom, Denise, Schnitzlein, Carla W., Chong, Yohana Geomar Macías Yen , Dizon, Don S. , Cathcart-Rake, Elizabeth J , Chong, Yee Won

CA: A Cancer Journal for Clinicians | December 9, 2024 | Volume: 75 | Issue: 1 | Pages: 68-81

10.3322/caac.21872 | PMID 39652385 Get It

Abstract In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is physically and psychologically taxing—and, in some, traumatic. However, for transgender and gender‐diverse (TGD) people, many of whom have experienced discrimination in myriad health care settings, the challenges may be even greater. These recommendations focus on how best to deliver quality cancer care to transgender men (individuals who identify as men but were assigned female sex at birth), transgender women (individuals who identify as women but were assigned male sex at birth), and people who identify somewhere beyond this gender spectrum as nonbinary or using other terms, based on the available, albeit sparse, literature. This review broaches: (1) the epidemiology of cancer in TGD individuals, including the incidence of cancer and cancer‐related mortality; (2) cancer center practices that are welcoming and affirming to TGD patients; (3) the need for awareness and intentionality in the spaces of diagnosis and treatment for cancer; (4) the inevitable conclusion that gender differences exist but much more needs to be learned about the impact of gender‐affirming therapy, consisting of gender‐affirming surgeries and gender‐affirming hormone therapy, on cancer therapy; and (5) the efficacy and perceived safety of antineoplastic therapy and gender‐affirming hormone therapy.